bioZhena Corporation 5/13/ Private Placement Offering and/or Strategic Alliance Proposal bioZhena Corporation

Target Customers’ Profile 30% Sub-fertile 70% Birth control 100% Cervical health cancer, STDs Three statistics tell the story Personalized medicine - diagnostic tools $232 Billion personalized medicine market to grow 11% annually said PricewaterhouseCoopers

bioZhena Corporation 70% of women “would switch” 70% of women who would buy the Ovulona Smart Sensor, would switch from their current birth control to our fertility status monitor [from a survey of 5,000 US women]

bioZhena Corporation Cervical Cancer/STD Screen Innocuous affordable triage for colposcopy-biopsy As the sensor monitors cervical tissues, other STDs will be detected. Sexually Transmitted Diseases Billions women globally. Tens of millions reproductive-age women in the U.S. alone. This screen is for everyone. Affordable. Private. Solid.

bioZhena Corporation Friendly Technology From Home to Healthcare Providers From patients’ Ovulona™ units to physician’s Ovulograph™ – when needed

bioZhena Corporation Applications, apps Helping to Conceive Pregnancy Managing Menstrual Cycle Natural Birth Control Managing Menopause Cervical Cancer, STD Screening

bioZhena Corporation 5/13/2015bioZhena Corporation7 Total Available Market Total Available Market Cervical cancer screening is an estimated annual $5B US Pap smear test market. Worldwide extrapolation: >$100B annually. Ovulona™ will save an est. 50% - 90%. Segments of bioZhena’s target market: Trying to Conceive Pregnancy Market Managing Menstrual Cycle Market Birth Control Market Managing Menopause Market Cervical Health Screening Market U.S. ~$ 25B World >$500B

bioZhena Corporation bioZhena Corporation’s Offering Personalized Health Management Contact